Citations

Showing 10 of 107961 citations.

Immune Checkpoint Inhibitors and Allograft Rejection Risk: Emerging Evidence Regarding Their Use in Kidney Transplant Recipients
Khan, Muhammad Ali , Mehmood, M , Azzazi, Hind El , Shaikh, Samiullah , Bhasin, Bhavna , Gudsoorkar, Prakash , Nair, S. , Kodali, Lavanya , Mour, Girish , Swaminathan, Sundararaman , Jawdeh, Bassam G. Abu , Mehmood, Munir , El Azzazi, Hind , Nair, Sumi S , Abu Jawdeh, Bassam G , Mour, Girish K , Khan, Muhammad Ali

Mayo Clinic

Journal of Clinical Medicine | July 21, 2025 | Volume: 14 | Issue: 14 | Pages: 5152

10.3390/jcm14145152 | PMID 40725844 Get It

The indications for immune checkpoint inhibitor (ICI) use in cancer treatment continue to expand. This is attributable to their proven anticancer activity in addition to their tolerability and favorable toxicity profile as compared to conventional chemotherapeutic agents. ICIs work by blocking the inhibitory signals between tumor cells and T-cells, thereby enhancing the T-cell cytotoxic activity to inhibit tumor growth. Because of their immune-stimulating effect, ICIs are linked to adverse renal outcomes in both native and transplanted kidneys. The risk of kidney allograft rejection in the setting of ICI use has been reported to be around 40%, leading to an increased risk of graft loss. In this report, we review the literature examining outcomes in kidney transplant recipients receiving ICIs for various oncologic indications.
Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy
Chan, Emily , Pugh, Stephanie L. , Simko, Jeffry, Feng, Felix Y. , Shipley, William U. , Lukka, Himanshu, Bahary, Jean‐Paul, Pisansky, Thomas M. , Zeitzer, Kenneth L. , Gore, Elizabeth , Balogh, Alexander G., Lovett, R.D., Wong, Anthony , Dess, Robert T. , McGinnis, L.S., Kuettel, Michael, DeMora, Luda, Dess, Robert T , Bahary, Jean-Paul , Efstathiou, Jason A. , Rosenthal, Seth A. , DeMora, Luda, Sandler, Howard M.

Mayo Clinic

The Prostate | July 21, 2025 | Volume: 85 | Issue: 14 | Pages: 1315-1322

10.1002/pros.70018 | PMID 40686005 Get It

ABSTRACTBackgroundWe aim to evaluate whether increased lymph node yield at prostatectomy (RP) is associated with improved outcomes in NRG/RTOG 9601, a randomized clinical trial of men who underwent either radiation (RT) alone or RT + bicalutamide for PSA elevation following RP for pT2/T3 prostate cancer.MethodsWe reviewed available pathology reports for patients in NRG/RTOG 9601 to determine the nodal count at RP. Cox proportional hazards models were used to assess effect of lymph nodes yield, arm (RT alone or RT + bicalutamide), Gleason score, positive margins, and seminal vesicle invasion on the following endpoints: times to local and distant failure and overall and disease‐specific survival.ResultsOf 760 patients, 552 (73%, 276 in each arm) had complete data available. Median node count in the entire cohort was 6 (range: 0–33, IQR: 3–9). There were no significant differences between arms in terms of patient demographic or clinical characteristics, including total lymph nodes removed in either arm. There was no significant association between total lymph nodes and overall or disease‐specific survival with both arms combined and when adjusting for arm. Notably, interaction analysis revealed that in seminal vesicle invasion, there was a significant association between lymph node yield and OS and DSS (HR = 0.91, 95% CI: 0.83–0.99, p = 0.034; HR = 0.87, 95% CI: 0.77–0.99, p = 0.029, respectively).ConclusionsAlthough lymph node yield in NRG/RTOG 9601 did not show association with adverse outcomes in the entire cohort or either arm alone, there was significant association between lymph node yield and adverse outcomes when seminal vesicle invasion was present. The therapeutic benefit of extensive lymph node dissection remains uncertain but could be more relevant in higher risk patients.
Single-cell multiomics identifies both shared and unique features of immune dysfunction in Parkinson’s disease and inflammatory bowel disease colon, plasma and stool
Buendia, Marc, Shi, Ji , Kachergus, Jennifer M., Efron, Philip A. , Alvarez, Stephan D. , Xue, Qing‐Shan, Zimmermann, Ellen M. , Forsmark, Christopher E. , Thompson, E. Aubrey, Bolen, MacKenzie L. , Buendia, Marc, Staley, Hannah A. , Park, Gwoncheol , Nagpal, Ravinder , McFarland, Nikolaus R. , Menees, Kelly B , Salas, Azucena , Thompson, E. Aubrey, Tansey, Malú G.

Mayo Clinic

No container title available | July 21, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7115293/v1 Get It

Abstract Parkinson’s disease (PD) is the fastest growing neurodegenerative disease in the world1. Gastrointestinal (GI) dysfunction can occur decades before motor impairments and in up to 80% of individuals living with PD2,3,4. We investigated peripheral relationships that may underlie environmental contributions to mechanisms along the gut-blood axis that contribute to PD pathogenesis. Single-cell multiomic spatial molecular imaging (SMI) of colonic tissue localized inflammatory injury within epithelial cells that appear to be associated with iron mishandling in both inflammatory bowel disease (IBD) and PD biosamples. We found that both the single-cell SMI of RNA and protein revealed parallel cross-modal dysregulation in the gut epithelium, in both IBD and PD biosamples. These data are accompanied by plasma (PD) and stool (IBD) protein depletion of CCL22. Our findings suggest iron mishandling along the gut barrier likely contributes to systemic inflammation, which may be the catalyst that primes circulating immune cells to body-first PD pathogenesis.
Activity of Phage and Vancomycin in a Murine Staphylococcus aureus Periprosthetic Joint Infection Model Managed With Debridement and Implant Retention
Herren, Sebastian , Karau, Melissa J. , Perez, Sergio F. Guarin , Koscianski, Christina, Mandrekar, Jayawant N. , Patel, Robin , Bedard, Nicholas A. , Herren, Sebastian C , Guarin Perez, Sergio F , Patel, Robin , Bedard, Nicholas A

Mayo Clinic

Journal of Orthopaedic Research | July 21, 2025 | Volume: 43 | Issue: 10 | Pages: 1767-1775

10.1002/jor.70029 | PMID 40685695 Get It

ABSTRACT Periprosthetic joint infection (PJI) is a serious complication of total joint arthroplasty (TJA), with Staphylococcus aureus being one of the most common causative organisms. Irrigation and debridement with component retention (IDCR) is often performed to manage PJI. Antimicrobial treatment that targets S. aureus biofilms on prosthesis surfaces and within bone may be especially helpful when retaining a prosthesis. Phages, viruses that specifically infect bacteria, are a potential therapeutic consideration. Using a biofilm time kill assay in bovine synovial fluid, bactericidal activity of vancomycin or phage K (32 µg/mL and 10 11 pfu/mL, respectively) as well as the combination of phage K (10 10 pfu/mL) and vancomycin (32 µg/mL) was observed against a methicillin‐resistant S. aureus (MRSA) strain. Using a murine PJI model, mice infected with MRSA underwent IDCR followed by phage administration into the joint space with or without systemically administered vancomycin. Mice receiving both phage and vancomycin had significant reductions in MRSA on the prosthesis surface compared to untreated or vancomycin‐treated mice. Phage K showed bactericidal activity in vitro and was active when locally delivered in combination with systemically administered vancomycin in a murine PJI model managed with IDCR.
Novel Subxiphoid Cut Down Approach to Facilitate Epicardial Catheter Ablation in an Obese Patient
Raina, Anvi , Mulpuru, Siva K. , DeSimone, Christopher V. , DeSimone, Christopher V

Mayo Clinic

Journal of Cardiovascular Electrophysiology | July 21, 2025 | Volume: 36 | Issue: 9 | Pages: 2440-2444

10.1111/jce.70022 | PMID 40685503 Get It

ABSTRACTIntroductionDry epicardial access to facilitate epicardium mapping and ablation is a well described technique with increasing use in modern electrophysiology. However, traditional percutaneous access can be challenging is obese patients or those with anatomical variations.Methods and ResultsWe report on a case where a subxiphoid cut down was utilized for epicardial access in a patient with morbid obesity. This approach allows us to reach the epicardial space when traditional needles do not suffice and enables a more controlled access, potentially minimizing the risk of damage to nearby structures.ConclusionSubxiphoid cut down to facilitate percutaneous epicardial access is a simple and effective option when traditional epicardial access is not feasible due to morbid obesity or anatomical variations.
A Radiomic Approach to Clinical MRI Refines the Thalamus‐Cognition Link in Multiple Sclerosis
Buyukturkoglu, Korhan , Davis, Levi, Orellana, Renán A., Sun, Rongyi , Özçelik, Sinem , Isenstein, Nina M., Onomichi, Kaho, Iqbal, Rifat, Zhao, B., Stern, Yaakov E. , Zeydan, Burcu , Kantarci, Orhun H. , Jager, Philip L. De , Zeydan, Burcu , Lin, Lu , Davis, Levi, Orellana, Renan E., Iqbal, Rifat, Stern, Yaakov, Riley, Claire

Mayo Clinic

Journal of Neuroimaging | July 21, 2025 | Volume: 35 | Issue: 4 | Pages: No page available

10.1111/jon.70069 | PMID 40685506 Get It

ABSTRACT Background and Purpose Radiomics extracts imaging features that may not be detectable through conventional volumetric analyses. Given their role in multiple sclerosis (MS), we applied radiomics to thalamic nuclei and examined their associations with cognitive performance. Methods A total of 601 individuals were included (342 people with MS [PwMS] from two cohorts and 259 healthy controls [HC]). Radiomic features (RF) and volumes were extracted from the whole thalamus, five thalamic nuclei, and the putamen segmented on three‐dimensional T1‐weighted images. Cognitive performance was assessed using the Symbol Digit Modalities Test (SDMT) and Paced Auditory Serial Addition Test (PASAT) in PwMS and the Digit Symbol Substitution Test (DSST) in HC. In the first MS cohort, multivariate linear regression in a discovery set ( N = 103) identified thalamus‐derived RF associated with SDMT, which were retested in a replication set ( N = 63). Their associations with PASAT in a second MS cohort ( N = 176) and DSST in HC were also evaluated. We then tested whether the same RFs, when extracted from the putamen, was associated with SDMT. Least Absolute Shrinkage and Selection Operator (LASSO) models assessed the combined predictive value of RF and volumes. Results Twenty‐eight RF–region of interest (ROI) pairs were associated with SDMT in the replication set (false discovery rate [FDR] < 0.05). Of these, 24 were also associated with PASAT (FDR ≤ 0.03), and 2 with DSST. Only ventral nuclei volume showed replicated associations among volumetrics. Only four putamen‐derived pairs were associated with SDMT (FDR = 0.04). LASSO results confirmed RF outperformed volumes. Conclusion RF extracted from the thalamus is strongly associated with cognitive performance in PwMS, outperforming volumetric measures and supporting their potential as sensitive imaging biomarkers.
MRI characteristics during attack and remission distinguish patients with MOG antibody-associated disease from multiple sclerosis
Cacciaguerra, Laura , Tajfirouz, Deena , Redenbaugh, Vyanka , Krecke, Karl N. , Thakolwiboon, Smathorn , Madhavan, Ajay A. , Tillema, Jan-Mendelt , López‐Chiriboga, A. Sebastian , Chen, John J. , Syc-Mazurek, Stephanie B , Cacciaguerra, Laura , Tajfirouz, Deena , Thakolwiboon, Smathorn , Madhavan, Ajay A , Valencia Sanchez, Cristina , Sechi, Elia , Pittock, S J , Flanagan, E P , Chen, John J , Syc‐Mazurek, Stephanie B. , Dinoto, Alessandro , Tillema, Jan‐Mendelt , Valencia-Sánchez, Cristina , Sechi, Elia , Pittock, Sean J. , Flanagan, Eoin P.

Mayo Clinic

Journal of Neurology, Neurosurgery & Psychiatry | July 20, 2025 | Volume: No volume available | Issue: No issue available | Pages: jnnp-2025-336684

10.1136/jnnp-2025-336684 | PMID 40685157 Get It

Background Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and multiple sclerosis (MS) have both overlapping and distinct MRI lesion features, which vary with imaging timing. This study identified distinguishing MRI characteristics using paired MRIs at clinical attack and remission. Methods We retrospectively identified Mayo Clinic patients with MOGAD and MS that: (1) fulfilled respective diagnostic criteria; (2) had paired attack (≤30 days) and remission MRI scans (≥12 months) without interval attacks. MRIs were compared between groups for key features. Results We included 43 patients with MOGAD (median age 31 years (range, 3–67); 63% female) and 49 patients with MS (median age 39 years (range, 17–65); 65% female). Resolution of at least one T2-lesion differentiated MOGAD from MS (sensitivity, (95% CI 77% to 100%), specificity, (95% CI 86% to 99%); Youden’s index (YI)=0.90). Resolution of at least two T2-lesions indicated MOGAD (sensitivity 62% (95% CI 41% to 79%); specificity, 100% (95% CI 94% to 100%); YI=0.62). MOGAD patients were more likely to have normal MRI scans at follow-up compared with MS (brain 14/44 (32%) vs 0/60 (0%), p<0.001; spine 21/27 (78%) vs 7/36 (19%), p<0.001). In addition, the presence of T1-hypointense, ovoid periventricular T2, and enhancing lesions were more common in MS versus MOGAD at attack and remission and in the spine, longitudinally extensive T2 lesions were more common in MOGAD attacks (8/27 (30%)). Conclusion Paired MRI at attack and remission revealed distinctive characteristics of MOGAD and MS, with greater diagnostic value at remission driven by the discriminating power of T2-lesion resolution. In MOGAD patients with initial parenchymal involvement, a 1-year follow-up MRI may aid diagnosis and serve as a new baseline.
Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies
Goldman, Jennifer G. , Leverenz, James B., Blanc‬, ‪Frederic, Halliday, Glenda M. , Kantarci, Kejal, Lewis, Simon J.G. , Medsger, Helen Bundy, O’Brien, John T. , Scholz, Sonja W. , Ikeda, Manabu , Kantarci, Kejal , Blanc, Frédéric , O'Brien, John Tiernan , Halliday, Glenda , Goldman, Jennifer G , Scholz, Sonja W , Lewis, Simon J G , Kantarci, Kejal , Boeve, Bradley F. , Galasko, Douglas , Taylor, John‐Paul , Galvin, James E. , Leverenz, James B. , Lemstra, Afina W. , Leroi, Iracema , Litvan, Irene , Aarsland, Dag , McKeith, Ian G. , Taylor, Angela E.

Mayo Clinic

Alzheimer's & Dementia | July 20, 2025 | Volume: 21 | Issue: 7 | Pages: No page available

10.1002/alz.70470 | PMID 40684248 Get It

Abstract Dementia with Lewy bodies (DLB), a progressive neurodegenerative disease with heterogeneous clinical presentations, greatly impacts patients, caregivers, and society. Despite its frequency, diagnosing and treating DLB remains challenging. Advances in in vivo biomarker assays reflecting underlying pathology are improving disease identification, diagnostic accuracy, and therapeutic development for biologically targeted, disease‐modifying agents. Consequently, definitions of Alzheimer's disease and Parkinson's disease (PD) have shifted to focus on pathological changes occurring before clinical features, with proposed frameworks for detecting pathological amyloid and tau, neurodegeneration, and other markers (National Institute on Aging‐Alzheimer's Association) and alpha‐synucleinopathy and dopaminergic degeneration (Neuronal α‐synuclein Disease Integrated Staging System, SynNeurGe). The biological frameworks, particularly those related to alpha‐synuclein (α‐synuclein), have sparked debate about unifying DLB and PD under a single pathobiologic disease. This paper discusses the implications of these biological frameworks for the DLB community, addressing topics regarding multiple pathologies and neurochemical systems, clinical heterogeneity, and functional impairment, and exploring the potential impact on clinical trials and care. Highlights DLB is a progressive neurodegenerative disease with varied clinical presentations. Diagnosing and treating DLB remains challenging despite its frequency. Biological frameworks are reshaping Alzheimer's and Parkinson's definitions. In vivo biomarkers are improving DLB identification and diagnostic accuracy. Debate exists regarding unifying DLB and Parkinson's under one pathobiology.
Real‐world epilepsy monitoring with ultra‐long‐term subcutaneous electroencephalography: A 15‐month prospective study
Viana, Pedro F. , Biondi, Andrea , Winston, Joel S. , Freestone, Dean R. , Brinkmann, Benjamin H. , Richardson, Mark P. , Duun-Henriksen, Jonas , Biondi, Andrea , Winston, Joel S , Freestone, Dean R , Schulze-Bonhage, Andreas , Brinkmann, Benjamin H , Richardson, Mark P , Viana, Pedro F , Duun‐Henriksen, Jonas , Schulze‐Bonhage, Andreas

Mayo Clinic

Epilepsia | July 19, 2025 | Volume: 66 | Issue: 11 | Pages: 4476-4489

10.1111/epi.18566 | PMID 40682766 Get It

Abstract Objective Novel subcutaneous electroencephalography (sqEEG) systems enable prolonged, near‐continuous cerebral monitoring in real‐world conditions. Nevertheless, the feasibility, acceptability and overall clinical utility of these systems remain unclear. We report on the longest observational study using ultra‐long‐term sqEEG to date. Methods We conducted a 15‐month prospective, observational study including 10 adult people with treatment‐resistant epilepsy. After device implantation, patients were asked to record sqEEG, to use an electronic seizure diary, and to complete acceptability and usability questionnaires. sqEEG seizures were annotated visually, aided by automated detection. Individualized temporal patterns of seizure occurrence were assessed via circadian circular statistics and via Fano factor analysis. Results Over a median duration of 438 days, 10 patients recorded a median 18.8 h/day, totaling 71 984 h of real‐world sqEEG data. Adherence and acceptability remained high throughout the study. Although 754 sqEEG seizures were recorded across patients, more than half (52%) of these were not reported in the patient diary. Of the 140 (27%) diary reports not associated with an identifiable sqEEG seizure, the majority (68%) were reported as seizures with preserved awareness. The sqEEG to diary F1 agreement score was highly variable, ranging from .06 to .97. Patient‐specific patterns of circadian seizure occurrence and seizure clustering were found, including several relevant discrepancies between sqEEG and diary. Significance We demonstrate feasibility and high acceptability of ultra‐long‐term (months–years) sqEEG monitoring. These systems help provide real‐world, more objective seizure counting compared to patient diaries. It is possible to objectively monitor individual temporal fluctuations of seizure occurrence.
Beyond “other”: Exploring representation of minoritized individuals in headache research
Cheng, Nan , Singh, Rashmi B. Halker , Halker Singh, Rashmi B , Cheng, Nan

Mayo Clinic

Headache: The Journal of Head and Face Pain | July 19, 2025 | Volume: 65 | Issue: 8 | Pages: 1460-1461

10.1111/head.15013 | PMID 40985132 Get It